ACQUISITIONS (Details) (USD $)	3 Months Ended								12 Months Ended												12 Months Ended				12 Months Ended
	Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Oct. 01, 2011	Jul. 02, 2011	Mar. 30, 2013	Mar. 31, 2012	Apr. 02, 2011	Mar. 30, 2013 Pall Corporation [Member]		Mar. 31, 2012 Pall Corporation [Member]		Aug. 01, 2012 Pall Corporation [Member]	Dec. 28, 2010 Applied Critical Care Services, Inc. [Member]	Mar. 30, 2013 Acquired Technology [Member] Pall Corporation [Member]	Mar. 30, 2013 Customer Relationships [Member] Pall Corporation [Member]	Dec. 28, 2010 Customer Relationships [Member] Applied Critical Care Services, Inc. [Member]	Mar. 30, 2013 Acquired Technology and Customer Relationships [Member] Pall Corporation [Member]	Aug. 01, 2012 Replication and Delivery of Certain Manufacturing Assets [Member] Pall Corporation [Member]	Aug. 01, 2012 Term Loan [Member] Pall Corporation [Member]	Sep. 29, 2012 Purchase Price Allocation Adjustments [Member] Pall Corporation [Member]	Mar. 30, 2013 Reportable Segment [Member]	Mar. 31, 2012 Reportable Segment [Member]	Apr. 02, 2011 Reportable Segment [Member]	Mar. 31, 2012 Whole Blood [Member] Reportable Segment [Member]	Apr. 02, 2011 Whole Blood [Member] Reportable Segment [Member]	Mar. 30, 2013 Whole Blood [Member] Reportable Segment [Member] Pall Corporation [Member]
Business Acquisition [Line Items]
Purchase price																$ 535,200,000	$ 6,400,000
Consideration sransferred, share amount																500,000
Contingent consideration, maximum																						15,000,000
Face amount of debt																							475,000,000
Inventories												49,917,000												(2,500,000)
Property, plant and equipment												85,984,000												15,300,000
Intangible assets												188,500,000						61,000,000	127,500,000	4,500,000				(18,300,000)
Other assets/liabilities, net												(6,166,000)					800,000
Goodwill	330,474,000				115,058,000				330,474,000	115,058,000	115,367,000	216,940,000					2,700,000							9,900,000
Fair value of net assets acquired												535,175,000
Assumed liabilities																								(4,400,000)
Useful life																					12 years
Amortization expense									22,100,000	11,400,000	11,100,000										10,500,000
Net revenues	249,942,000	247,395,000	218,178,000	176,475,000	186,670,000	191,160,000	179,445,000	170,569,000	891,990,000	727,844,000	676,694,000														757,765,000	594,933,000	551,836,000	0	0	138,436,000
Net income	12,562,000	9,904,000	6,547,000	9,787,000	17,805,000	18,254,000	13,880,000	16,947,000	38,800,000	66,886,000	79,980,000
Cost of goods sold									463,859,000	358,604,000	321,485,000
Net sales												963,923,000		963,643,000
Net income												56,540,000		77,984,000
Basic earnings per share												$ 1.10		$ 1.54
Diluted earnings per share												$ 1.08		$ 1.51
Transaction costs												3,184,000	[1]	3,000,000	[1]
Amortization of inventory fair value adjustment												11,948,000	[2]	(11,948,000)	[2]
Amortization of acquired intangible assets												(5,236,000)	[3]	(15,708,000)	[3]
Interest expense incurred on acquisition financing												(3,173,000)	[4]	(9,520,000)	[4]
Selling, general and administrative expenses												(3,513,000)	[5]	(10,540,000)	[5]
Amount of transaction prior to acquisition																10,000,000
Amount owed																$ 1,400,000

[1] Eliminated transactions costs as these non-recurring costs were incurred in fiscal 2013.

[2] Added additional expense in the period ended March 31, 2012 to reflect the inventory fair value adjustments which would have been amortized had the transaction been consummated on April 3, 2011 as the corresponding inventory would have been completely sold during the first two quarters of 2011. Also, deducted the actual inventory fair value adjustment recorded in the fiscal year ended March 30, 2013 to reflect the pro-forma consumption of inventory in 2011.

[3] Added additional amortization of the acquired whole blood intangible assets recognized at fair value in purchase accounting.

[4] Added additional interest expense for the debt used to finance the acquisition.

[5] Additional investments in infrastructure costs to replicate certain support functions performed by division or corporate organizations of Pall that did not transfer in the acquisition. These costs are primarily related to information technology infrastructure and application costs, and personnel costs required to expand regional and corporate administrative and sales support functions. These costs are not intended to be representative of actual costs incurred by Pall Corporation, and represent Haemonetics' best estimate of future incremental costs on an annualized basis. Actual incremental investments may differ from these estimates.